Premium
Effects of clofibrate and a fat‐modified diet on serum lipids
Author(s) -
Brown Helen B.,
Lewis Lena A.,
Page Irvine H.
Publication year - 1975
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1975172171
Subject(s) - clofibrate , hyperlipidemia , medicine , triglyceride , endocrinology , cholesterol , serum cholesterol , blood lipids , chemistry , diabetes mellitus
The combined effect of clofibrate and a fat‐modified diet was determined in 17 hyperlipidemic patients: 7 type IIA, 7 type IV, 2 type VI(IIB), and I type III. Control serum lipid levels and lipoprotein patterns and their alteration with a fat‐modified diet had been determined previously 1/2 to 2 years for 3 patients, and 6 to 10 years for 14 patients. Two grams of clofibrate a day (0.5 gm four times daily) was taken along with the fat‐modified diet for 2 to 6 months by 5 patients and for 2 years by 13 patients. The effect of clofibrate and a fat‐controlled diet was also determined in 10 normolipidemic men who were subjects of an 18‐day test in which the polyunsaturated fat diet was quantitatively prepared and eaten along with 2 gm clofibrate a day (0.5 gm four times daily). The effect of clofibrate on serum cholesterol levels was a further mean reduction in type IIA patients by 19%, in type III by 23%, in type IV by 12%, in type VI by 7%, and in normolipidemic subjects by 8%. The extent of the additional serum cholesterol reduction with clofibrate in individual hyperlipidemic patients varied from + 10% to −44 % and was not related directly to the type of hyperlipidemia. The extent of reduction appeared related directly to the level of −S 40‐70 (similar to S f 12‐20) lipoproteinjraction in the control serum sample. Serum triglyceride levels were unaffected in type IIA and normolipidemic subjects. Serum triglyceride levels did not change consistently in the 2 type VI patients, rising by 11 % in 1 and dropping by 31% in the other. Serum triglyceride levels were significantly (p = 0.001) and consistently reduced by 39% only in type IV patients.